Marina Chiara Garassino to Cell Line, Tumor
This is a "connection" page, showing publications Marina Chiara Garassino has written about Cell Line, Tumor.
Connection Strength
0.309
-
Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin Cancer Res. 2019 02 01; 25(3):989-999.
Score: 0.109
-
Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol. 2011 Jan; 22(1):235-237.
Score: 0.064
-
LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments. J Thorac Oncol. 2021 08; 16(8):1298-1311.
Score: 0.033
-
Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. Clin Cancer Res. 2019 04 01; 25(7):2166-2173.
Score: 0.028
-
Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. J Exp Clin Cancer Res. 2018 Dec 04; 37(1):302.
Score: 0.028
-
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib. Sci Rep. 2018 01 17; 8(1):948.
Score: 0.026
-
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget. 2015 Oct 06; 6(30):30072-87.
Score: 0.022